In addition, treating this mixture of immune cells with the immune checkpoint inhibitors (anti-CTLA4 and anti-PD1), which allow for downregulation of Tregs, proper activation of CTL, Th, and memory T cells, with subsequent suppression of tumor cells through downregulation of CD133, CD34, and CD44. Here, CTLA4 is linked to neoplasm.